3Shan NT,Kris MG,Pao W,et al. Practical management of patients with. non small2cellLung cancer treated with gefitinib [J]. J Clin Oncol, 2005,. 23 ( 1 ) : 165.
4Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non2small cell lung cancer[J]. Imng Cancer,2003,40(3) :339.
5Tamura K, Yamamoto N, Takeda K, et al. Am epidemiologi cal survey for interstitial lung disease induced by gefitinib in pa tients with advanced nonsmall cell lung cancer. West Japan Thoracic Oncology Group (WJTOG)[J]. EurJ Cancer,2003,1 (5) :S21.
8Joensuu H, Roberts PT,Sarlomo-Rikala M,etal. Effect of the tyrosine kinase inhibitors STI 571 in a patient with a metastatic gastrointestinal stromal tumor[J]. N Engl J Med, 2001,344 (14) : 1502.
9Elliortt MA, Mesa RA, Tefferi A. Adverse events after,imatinib mesylate therapy[J]. N Engl J Med,2002,346(9) :712.
10Burton C, Azzi A, Kerridge I, et al. Adverse events after imatinib mesylate therapy[J]. N Engl J Med,2002,46(9):712.
